A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis.
about
Immunotherapy of systemic sclerosisManagement of Systemic-Sclerosis-Associated Interstitial Lung DiseaseSystemic sclerosis: current concepts in pathogenesis and therapeutic aspects of dermatological manifestations.Corticosteroids and the risk of scleroderma renal crisis: a systematic review.Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist's point of view.Nailfold videocapillaroscopy micro-haemorrhage and giant capillary counting as an accurate approach for a steady state definition of disease activity in systemic sclerosis.High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy.Lung involvement in systemic sclerosis.Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studiesTreatment of early diffuse systemic sclerosis skin disease.Biomarkers for skin involvement and fibrotic activity in scleroderma.Treatment of interstitial lung diseases associated with connective tissue diseases.Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries.Update on systemic sclerosis.Development of a Composite Outcome Measure for Systemic Sclerosis Related Interstitial Lung DiseaseRecent advances in connective tissue disease related interstitial lung disease.Current and emerging treatment options for interstitial lung disease in patients with rheumatic disease.Interstitial lung disease in systemic sclerosis: current and future treatment.Cyclophosphamide in systemic sclerosis: still in search of a 'real life' scenario.[Therapeutic management in early disease stages of systemic sclerosis : early diagnosis - early symptoms - early problems].Oral cyclophosphamide for active scleroderma lung disease: a decision analysis.Correction: Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies.Clinical characteristics of autoimmune rheumatic disease-related organizing pneumonia.Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials.Evaluation and management approaches for scleroderma lung disease.Scleroderma Lung DiseaseSystemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement—a retrospective study
P2860
Q24634395-FB3DFC7F-D571-4ED7-BC5E-E64E98B43092Q26799573-A175D953-C147-487E-B2C8-4EBC7D359C5AQ31125829-3CB6E0B2-708D-4089-840C-B5FB5C34EF0AQ33763415-A94952D3-51A4-4C56-94B3-DCFC28F565B2Q33907242-168B78A2-83E5-48E3-A795-7BA91EDBFD88Q34416725-A7534031-7353-48EA-889D-40DA7D921BBAQ34605114-74CD5E2F-EABD-4958-96FA-1C343FD507FDQ34732817-EFA34F65-87A7-424F-808E-159063925B41Q35121494-EC968EAD-D54A-4C1E-B6AD-25E2E6B40030Q37304301-EC4DA7A1-820A-4891-9957-B3EEB7094304Q37467457-6185E203-B7F7-4E04-9411-F5BD45E6D18AQ37912251-485E9137-4F61-4C67-87C0-BE78E0A4F444Q37990559-32665608-E3A8-4F25-8C1F-407461CCBF5AQ38163917-1A71AF74-AD9A-428C-83E6-1D461932A596Q38542317-603A4E11-0C5C-41D7-A027-CD068E5C6DFCQ38601342-8743DBD4-859E-473D-A4EC-076B860C5F85Q38678939-2C9700C1-4F46-4D1A-8F1D-FB310472A808Q38692232-5619546A-A8CD-4959-8E2F-F2DE6C1FD090Q38773637-9AC3CB46-315C-4044-A457-673E832CC9E7Q42963326-3E27FDE0-3AA9-4147-BA5E-0C0741C5A41BQ43612095-9E738295-2CFA-4393-A9B4-B7B78864F58DQ46015285-E503DC4E-7CAA-48A3-A50E-6A73663D0388Q46951824-6F305AEB-354A-4B42-BC70-DD038D19E8A2Q47819981-673E315A-995B-4527-A2A0-F1C3B06EFE34Q49166002-D7B493DA-72E2-4529-A37C-AD35A6D9AEFBQ50623134-9FD4DF60-D2A1-48C5-8C1E-00E77FD622C5Q52939870-2CCDF8BF-6F27-4B30-86A9-3CE71C5B1438Q56977976-1535C566-C46F-4016-9B35-60D913312DB7Q57076696-81891CCD-D6B2-41E9-A1DD-ADDB44F849B7
P2860
A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
A randomized unblinded trial o ...... eatment of systemic sclerosis.
@en
A randomized unblinded trial o ...... eatment of systemic sclerosis.
@nl
type
label
A randomized unblinded trial o ...... eatment of systemic sclerosis.
@en
A randomized unblinded trial o ...... eatment of systemic sclerosis.
@nl
prefLabel
A randomized unblinded trial o ...... eatment of systemic sclerosis.
@en
A randomized unblinded trial o ...... eatment of systemic sclerosis.
@nl
P2093
P1476
A randomized unblinded trial o ...... eatment of systemic sclerosis.
@en
P2093
M Fritzler
O Nadashkevich
W Kovalenko
P304
P356
10.1007/S10067-005-1157-Y
P577
2005-10-14T00:00:00Z